QDEL
NASDAQQuidelOrtho Corporation
SectorHealth CareIndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
Website
News25/Ratings12
News · 26 weeks60+125%
2025-10-262026-04-19
Mix4290d
- Insider22(52%)
- Other9(21%)
- SEC Filings6(14%)
- Earnings2(5%)
- Leadership2(5%)
- M&A1(2%)
Latest news
25 items- PRUnderstanding and Addressing Syphilis Trends - and What's Being MissedSAN DIEGO, April 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL), a global leader of in vitro diagnostics, has released episode 57 of its Science Bytes podcast, focusing on evolving syphilis trends in the United States and the rise of congenital syphilis cases despite declines in early-stage infections. Hosted by Josh Casey, the episode features Andrea Ott‑Vasconi, Director of Scientific Affairs and Regulatory at QuidelOrtho, who breaks down what CDC data reveals, why congenital syphilis continues to rise and how diagnostic strategies and healthcare workflows can
- INSIDERSEC Form 4 filed by Sisitsky Nathaniel4 - QuidelOrtho Corp (0001906324) (Issuer)
- PRTTP Group Announces the Sale of LEX DiagnosticsTTP today announced the acquisition by QuidelOrtho Corporation (NASDAQ:QDEL), a global leader in in vitro diagnostics, of LEX Diagnostics Limited, a UK-based molecular diagnostics company and a spin-out of TTP Group. Founded in 2020, LEX Diagnostics originated from a TTP innovation programme to translate a breakthrough in ultra-fast thermal control into a commercially viable diagnostic solution. This work led to the development of a point-of-care molecular testing platform capable of delivering PCR results in minutes. "At TTP, we identified the opportunity for ultra-fast thermal cycling to unlock the real potential of PCR at the point-of-care," said Dr Andrew Baker-Campbell, Chair and f
- PRQuidelOrtho Corporation Completes Acquisition of LEX Diagnostics– Marks a Milestone in QuidelOrtho's Plans to Accelerate Growth in Point-of-Care Molecular Diagnostics –– Expands Portfolio with Ultra-Fast PCR Platform Designed to Deliver Results in Approximately Ten Minutes or Less –– Company Expects to Initiate U.S. Commercial Launch of the LEX VELO System Later This Year –SAN DIEGO, April 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today it has completed the acquisition of LEX Diagnostics ("LEX") for cash consideration of approximately $100 million. The LEX VELO System received U.S. Food and Drug Administration ("FDA") 510(k) clearance and
- SECQuidelOrtho Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - QuidelOrtho Corp (0001906324) (Filer)
- PRQuidelOrtho Announces Preliminary Revenue for the First Quarter 2026 and Provides Update on Full-Year 2026 GuidanceSAN DIEGO, April 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, today announced preliminary unaudited revenue for the first quarter of 2026, ended March 29, 2026, and provided an update on its full-year 2026 financial guidance. The Company also announced its plan to release its full first quarter 2026 financial results on Tuesday, May 5, 2026, after the market closes. Preliminary Unaudited First Quarter 2026 RevenueThe Company currently expects preliminary unaudited revenue, as reported, o
- SECAmendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho CorporationSCHEDULE 13G/A - QuidelOrtho Corp (0001906324) (Subject)
- INSIDERSEC Form 3 filed by new insider Sisitsky Nathaniel3 - QuidelOrtho Corp (0001906324) (Issuer)
- INSIDERSEC Form 4 filed by Busky Joseph M.4 - QuidelOrtho Corp (0001906324) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho CorporationSCHEDULE 13G/A - QuidelOrtho Corp (0001906324) (Subject)
- INSIDERSEC Form 3 filed by new insider Hanson Bryan Michael3 - QuidelOrtho Corp (0001906324) (Issuer)
- SECQuidelOrtho Corporation filed SEC Form 8-K: Regulation FD Disclosure8-K - QuidelOrtho Corp (0001906324) (Filer)
- PRNathaniel Sisitsky Joins QuidelOrtho as Chief Legal OfficerSAN DIEGO, March 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, is pleased to announce the appointment of Nathaniel "Nate" Sisitsky as its new Chief Legal Officer, effective March 23, 2026. He will report to Brian Blaser, President and Chief Executive Officer, and will lead QuidelOrtho's global legal, compliance and corporate governance functions. Mr. Sisitsky brings more than 25 years of legal and governance experience advising public companies across life sciences and technology sectors.
- INSIDERAmendment: Chief Financial Officer Busky Joseph M. bought $79,742 worth of shares (3,370 units at $23.66) (SEC Form 4)4/A - QuidelOrtho Corp (0001906324) (Issuer)
- PRFaster Cardiac Answers with High‑Sensitivity TroponinSAN DIEGO, Feb. 19, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL), a global leader of in vitro diagnostics, has released episode 56 of its Science Bytes podcast, featuring Dr. Lindy Carlstrom, Global Medical Affairs Manager for Acute Care. In this episode, Carlstrom and host Josh Casey discuss how high-sensitivity troponin (hs troponin) is transforming early cardiac diagnosis and improving emergency department efficiency. Key InsightsFaster answers when time matters: hs troponin detects cardiac injury earlier than traditional assays, enabling quicker diagnosis and r
- SECSEC Form 10-K filed by QuidelOrtho Corporation10-K - QuidelOrtho Corp (0001906324) (Filer)
- PRQuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor ConferenceSAN DIEGO, Feb. 18, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced that members of its management team will present at the Raymond James 47th Annual Institutional Investor Conference. The Company's presentation is scheduled for Tuesday, March 3, 2026, at 1:40 p.m. ET / 10:40 a.m. PT. Interested parties can access the live webcast and replay in the "Events & Presentations" section of the "Investor Relations" page of QuidelOrtho's website at https://ir.quidelortho.com/
- SECSEC Form 8-K filed by QuidelOrtho Corporation8-K - QuidelOrtho Corp (0001906324) (Filer)
- INSIDERDirector Strobeck Matthew bought $239,586 worth of shares (10,000 units at $23.96), increasing direct ownership by 56% to 27,775 units (SEC Form 4)4 - QuidelOrtho Corp (0001906324) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho CorporationSCHEDULE 13G/A - QuidelOrtho Corp (0001906324) (Subject)
- INSIDERChief Financial Officer Busky Joseph M. bought $79,742 worth of shares (3,370 units at $23.66) (SEC Form 4)4 - QuidelOrtho Corp (0001906324) (Issuer)
- INSIDERPresident and CEO Blaser Brian J. bought $248,661 worth of shares (10,540 units at $23.59) (SEC Form 4)4 - QuidelOrtho Corp (0001906324) (Issuer)
- SECSEC Form SCHEDULE 13G filed by QuidelOrtho CorporationSCHEDULE 13G - QuidelOrtho Corp (0001906324) (Subject)
- SECQuidelOrtho Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - QuidelOrtho Corp (0001906324) (Filer)
- PRQuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results― Delivered 6% Labs and 9% TRIAGE™ growth, as reported, and 240 bps of adjusted EBITDA margin expansion in FY25 ― ― Continued growth and margin expansion expected in FY26; free cash flow expected to improve by over $200 million ― SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the fourth quarter and full-year ended December 28, 2025. "In 2025, we transitioned from COVID-driven volatility to a more durable, diversified diagno